CINV Existing and Pipeline Drugs Market : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
CINV Existing and Pipeline Drugs Market – Scope of Report
TMR’s report on the global CINV existing and pipeline drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global CINV existing and pipeline drugs market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global CINV existing and pipeline drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the CINV existing and pipeline drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global CINV existing and pipeline drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global CINV existing and pipeline drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global CINV existing and pipeline drugs market.
The report delves into the competitive landscape of the global CINV existing and pipeline drugs market. Key players operating in the global CINV existing and pipeline drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global CINV existing and pipeline drugs market profiled in this report.
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market CINV existing and pipeline drugs.
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
- Company websites, presentations, annual reports, white papers, technical paper, product brochure
- Internal and external proprietary databases and relevant patents
- National government documents, statistical databases, and market reports
- News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
- Industry Sources:
- Elsevier, Inc.
- National Institutes of Health (NIH)
- Department of Health Care Service
- Trade Data Sources
- Trade Map
- UN Comtrade
- Trade Atlas
- Company Information
- OneSource Business Browser
- Mergers & Acquisitions
- Thomson Mergers & Acquisitions
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
- Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
- Helps in validating and strengthening secondary research findings
- Further develops the analysis team’s expertise and market understanding
- Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
- Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
- Purchasing/Sourcing managers, technical personnel, distributors
- Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
- Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
- Advanced Oncotherapy PLC
- Danfysik A/S
- Hitachi, Ltd.
- IBA Worldwide
- Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- Table 1 : List of Abbreviations
- Table 2 : Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2021 & 2031)
- Table 3 : Chemotherapy Induced Nausea and Vomiting (CINV): Subtypes and Description
- Table 4 : Treatment Recommendations for CINV
- Table 5 : Event Impact Analysis: Global CINV Drugs Market
- Table 6 : Global CINV Drugs Market Revenue, by Major Drugs, 2017 - 2031
- Table 7 : Global CINV Estimated Patient Pool, by Major Drugs, 2017 - 2031 (Thousands)
- Table 8 : SWOT Analysis for SUSTOL
- Table 9 : Efficacy of SUSTOL with Difficult Chemo Regimens
- Table 10 : SWOT Analysis for Rolapitant
- Table 11 : Overview of Rolapitant Efficacy Analysis
- Table 12 : Global CINV Drugs Market Revenue, by Region, 2017 - 2031
- Table 13 : Global CINV Estimated Patient Pool, by Geography, 2017 - 2031 (Thousands)
- Table 14 : North America CINV Pipeline Drugs Market Revenue, 2017 - 2021
- Table 15 : North America CINV Estimated Patient Pool, by Pipeline Drug, 2017 - 2021 (Thousands)
- Table 16 : Europe CINV Pipeline Drugs Market Revenue, 2022 – 2031
- Table 17 : Europe CINV Estimated Patient Pool, by Pipeline Drug, 2022 – 2031 (Thousands)
- Table 18 : GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2017
- Table 19 : Helsinn Holding S.A.: Pipeline Product Portfolio
- Table 20 : Heron Therapeutics, Inc.: Expenses & Revenue, 2011 – 2017
- Table 21 : Heron Therapeutics, Inc.: Pipeline Product Portfolio
- Table 22 : Merck & Co., Inc.: Expenses & Revenue, 2011 – 2017
- Table 23 : Tesaro, Inc.: Expenses & Revenue, 2011 – 2017
- Table 24 : Tesaro, Inc.: Pipeline Product Portfolio
- Figure 1 : CINV Existing and Pipeline Drugs: Market Segmentation
- Figure 2 : Global CINV Drugs Market (US$ Mn), by Major Drugs, 2021
- Figure 3 : Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2017 & 2031 (Value %)
- Figure 4 : Pathogenesis of CINV
- Figure 5 : Unmet Needs in the CINV Market
- Figure 6 : Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2017 & 2031 (Value %)
- Figure 7 : Global Aloxi Market Revenue, 2017 - 2031
- Figure 8 : Global Zofran Generic Market Revenue, 2017 - 2031
- Figure 9 : Global Kytril Generic Market Revenue, 2017 - 2031
- Figure 10 : Global Emend Market Revenue, 2017 - 2031
- Figure 11 : Global Akynzeo Market Revenue, 2017 - 2021
- Figure 12 : Global SUSTOL Market Revenue, 2022 – 2031
- Figure 13 : Primary Efficacy Results: Complete Response with Patients Receiving MEC
- Figure 14 : Primary Efficacy Results: Complete Response with Patients Receiving HEC
- Figure 15 : Global Rolapitant Market Revenue, 2017 - 2021
- Figure 16 : North America CINV Drugs Market Revenue, 2017 - 2031
- Figure 17 : Europe CINV Drugs Market Revenue, 2017 - 2031
- Figure 18 : Asia Pacific CINV Drugs Market Revenue, 2017 - 2031
- Figure 19 : Latin America CINV Drugs Market Revenue, 2017 - 2031
- Figure 20 : Middle East & Africa CINV Drugs Market Revenue, 2017 - 2031
Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.